Tuesday, November 01, 2022
4:00PM – 5:00PM ET
Please note this TeleECHO program is 4:00PM Eastern, 3:00PM Central, 2:00PM Mountain and 1:00PM Pacific.
Ken H. Young, MD, PhD
Professor and Director, Hematopathology
Duke University Medical Center
Duke Cancer Institute
After completing the CME activity, learners should be better able to:
- Summarize concerns regarding therapeutic resistance in patients with multiple myeloma with relapsed/refractory disease treated in the community setting
- Evaluate current efficacy and safety data with CAR T-cell therapy in relapsing/refractory multiple myeloma
- Generate plans to appropriately sequence CAR-T therapy for patients and manage adverse events associated with CAR-T therapy
This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation Statement
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with management of patients with multiple myeloma.
CNE Credits: 1.0 ANCC Contact Hour.
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org